Lonza • AMYRA Biotech AG to develop a rational oral treatment for celiac disease using a cocktail of two proprietary enzymes • Contract covers the process development and production of AMYRA’s two enzymes for the treatment of celiac disease • Lonza will develop and manufacture AMYRA’s enzymes in their Kourim, Czech Republic facility • Included in the contract is an XSâ„¢ Commercial License with access to Lonza’s XSâ„¢ Microbial Expression Technology Platform Basel and Zug, Switzerland, 10 April 2014 –…